Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 45 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lorazepam Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg

NCT00649818
View directory record Official record
Conditions
Healthy
Interventions
Lorazepam Tablets 2 mg, Ativan Tablets 2 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 2 Interventional

Comparing Gabapentin and Lorazepam for Treating Alcohol Withdrawal

NCT00011297
View directory record Official record
Conditions
Alcoholism
Interventions
gabapentin (Neurontin), lorazepam (Ativan)
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2006 · Synced Jul 22, 2026, 2:04 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Lorazepam Effects on Neuroimaging Measures

NCT04671836
View directory record Official record
Conditions
Lorazepam, Neuroimaging
Interventions
Lorazepam 1Mg Tablet, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Jul 22, 2026, 2:04 PM EDT
Withdrawn Phase 1Phase 2 Interventional

GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1

NCT00123578
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Lorazepam, Pentobarbital
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Jul 22, 2026, 2:04 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Acute Effect of Lorazepam on Brain Activity Measured by Magnetoencephalograpy (MEG) and Electroencephalography (EEG)

NCT01272778
View directory record Official record
Conditions
Healthy Subjects
Interventions
Lorazepam, Placebo
Drug
Lead sponsor
Orasi Medical, Inc.
Industry
Eligibility
18 Years to 35 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Elk Grove Village, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2011 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 2 Interventional Results available

Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

NCT00807937
View directory record Official record
Conditions
Anxiety Disorders
Interventions
AZD7325, Lorazepam, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
51
States / cities
Mesa, Arizona • Little Rock, Arkansas • Carson, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2010 · Synced Jul 22, 2026, 2:04 PM EDT
Terminated Phase 2 Interventional Results available

Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy

NCT00429702
View directory record Official record
Conditions
Nausea, Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
Decadron®, Benadryl®, Ativan®, ondansetron hydrochloride
Drug
Lead sponsor
University of South Florida
Other
Eligibility
8 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Fort Myers, Florida • Orlando, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 4 Interventional Results available

Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder

NCT00721526
View directory record Official record
Conditions
Alcohol Dependence, Anxiety Disorder
Interventions
disulfiram plus lorazepam
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 4 Interventional

Treatment of Alcohol Withdrawal in Hospital Patients

NCT00249366
View directory record Official record
Conditions
Alcohol Withdrawal Syndrome
Interventions
Lorazepam (drug), Lorazepam
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Jul 22, 2026, 2:04 PM EDT
Terminated Phase 1 Interventional

How Your Patients' Non-REM Sleep Changes On Sedatives in the Intensive Care Units

NCT00826553
View directory record Official record
Conditions
Delirium, Respiratory Failure
Interventions
Dexmedetomidine, GABA agonist
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers

NCT00513565
View directory record Official record
Conditions
Depressive Disorder and Anxiety Disorders
Interventions
single dose
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Not applicable Interventional

A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal

NCT00523185
View directory record Official record
Conditions
Alcohol Withdrawal
Interventions
Lorazepam, Diazepam
Drug
Lead sponsor
Stanford University
Other
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2007 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms

NCT01780519
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
lorazepam
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 9, 2016 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 1 Interventional

Dextromethorphan to Treat Patients With Voice Spasms

NCT00055549
View directory record Official record
Conditions
Voice Disorders
Interventions
Dextromethorphan, Lorazepam
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

Paramedic Treatment of Prolonged Seizures by Intramuscular Versus Intravenous Anticonvulsant Medications

NCT00809146
View directory record Official record
Conditions
Status Epilepticus
Interventions
Intramuscular route of active treatment, Intravenous route of active treatment
Drug
Lead sponsor
Robert Silbergleit
Other
Eligibility
Not listed
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
17
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Jul 22, 2026, 2:04 PM EDT
Terminated Phase 4 Interventional Results available

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

NCT01362205
View directory record Official record
Conditions
Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity, Alcohol Withdrawal Hallucinosis, Alcohol Withdrawal-Induced Delirium Tremens
Interventions
Dexmedetomidine, Placebos
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 89 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Lorazepam-Induced Toxicity in the Aged

NCT00044642
View directory record Official record
Conditions
Anxiety Disorders, Generalized Anxiety Disorder
Interventions
Lorazepam
Drug
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
60 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
2
States / cities
New York, New York • Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 3 Interventional Results available

SM-1 vs 2 Comparators and Placebo in Participants With a History of Transient Insomnia.

NCT03331042
View directory record Official record
Conditions
Transient Insomnia
Interventions
SM-1, D+Z, D+L, Placebo
Drug
Lead sponsor
Sequential Medicine Ltd
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Jul 22, 2026, 2:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

NCT01949662
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lorazepam, Placebo, Haloperidol decanoate, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 22, 2026, 2:04 PM EDT
Not listed Phase 4 Interventional

Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit

NCT04156464
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Withdrawal Delirium
Interventions
Phenobarbital, Lorazepam
Drug
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome

NCT03090620
View directory record Official record
Conditions
Anticholinergics Toxicity
Interventions
Physostigmine, Lorazepam
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Jul 22, 2026, 2:04 PM EDT
Terminated Phase 3 Interventional

Clobazam Use in Epilepsia Partialis Continua - Pilot Study

NCT02134366
View directory record Official record
Conditions
Epilepsia Partialis Continua, Kojewnikov's Epilepsy, Epilepsy
Interventions
Clobazam, Clonazepam, Lorazepam
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Jul 22, 2026, 2:04 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)

NCT00621478
View directory record Official record
Conditions
Status Epilepticus
Interventions
lorazepam or diazepam
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
3 Months to 18 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
12
States / cities
Davis, California • Aurora, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Jul 22, 2026, 2:04 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

NCT03110900
View directory record Official record
Conditions
Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
Interventions
Haloperidol + lorazepam, Loxapine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Jul 22, 2026, 2:04 PM EDT